This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Adachi, Y. Articles by Curiel, D. T. Search for Related Content PubMed PubMed Citation Articles by Adachi, Y. Articles by Curiel, D. T.

Midkine Promoter-based Adenoviral Vector Gene Delivery for Pediatric Solid Tumors¹

Division of Human Gene Therapy, Departments of Medicine, Surgery, and Pathology [Y. A., P. N. R., M. Y., K. O., D. T. C.], Department of Pathology [W. E. G.], University of Alabama at Birmingham, Birmingham, Alabama, 35294; Department of Biochemistry, Faculty of Medicine, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima 890-8506, Japan [S. M.]; and Department of Biochemistry, Nagoya University School of Medicine, 65 Tsurumai-cho, Nagoya 446, Japan [T. M.]

It is important to develop a system to express therapeutic genes in tumor cells with sufficient selectivity for cancer gene therapy. Midkine (MK) is a newly identified heparin-binding growth factor that is transiently expressed in the early stages of retinoic acid-induced differentiation of embryonal carcinoma cells. It has been reported that many human malignant tumors express high levels of MK mRNA or protein. However, no MK expression is detected in human or mouse liver. These interesting features of MK led us to examine the MK promoter as a candidate for tumor-specific gene expression. We thus developed new recombinant adenoviral (Ad) vectors containing either luciferase reporter gene (AdMKLuc) or herpes simplex thymidine kinase gene (AdMKTK) under the control of the human MK promoter. AdMKLuc achieved relatively high activity in Wilms’ tumor (G-401) and neuroblastoma (SK-N-SH) cell lines. In addition, AdMKTK induced marked cell death in response to ganciclovir (GCV) in these same lines. Conversely, very low activity of the MK promoter was observed in mouse liver in vivo compared with the cytomegalovirus promoter. Importantly, AdMKTK + GCV did not induce liver toxicity, whereas substantial toxicity was seen with AdCMVTK + GCV treatment. On the basis of these findings, we conclude that the MK promoter is a candidate tumor-specific promoter for Wilms’ tumor or neuroblastoma.

This article has been cited by other articles:

				S. Sekine, K. Kataoka, Y. Fukuyama, Y. Adachi, J. Davydova, M. Yamamoto, R. Kobayashi, K. Fujihashi, H. Suzuki, D. T. Curiel, et al. A Novel Adenovirus Expressing Flt3 Ligand Enhances Mucosal Immunity by Inducing Mature Nasopharyngeal-Associated Lymphoreticular Tissue Dendritic Cell Migration J. Immunol., June 15, 2008; 180(12): 8126 - 8134. [Abstract] [Full Text] [PDF]

				J. Davydova, L. P. Le, T. Gavrikova, M. Wang, V. Krasnykh, and M. Yamamoto Infectivity-Enhanced Cyclooxygenase-2-Based Conditionally Replicative Adenoviruses for Esophageal Adenocarcinoma Treatment Cancer Res., June 15, 2004; 64(12): 4319 - 4327. [Abstract] [Full Text] [PDF]

				Y. Takei, K. Kadomatsu, S. Matsuo, H. Itoh, K. Nakazawa, S. Kubota, and T. Muramatsu Antisense Oligodeoxynucleotide Targeted to Midkine, a Heparin-binding Growth Factor, Suppresses Tumorigenicity of Mouse Rectal Carcinoma Cells Cancer Res., December 1, 2001; 61(23): 8486 - 8491. [Abstract] [Full Text] [PDF]

				Y. Adachi, P. N. Reynolds, M. Yamamoto, M. Wang, K. Takayama, S. Matsubara, T. Muramatsu, and D. T. Curiel A Midkine Promoter-based Conditionally Replicative Adenovirus for Treatment of Pediatric Solid Tumors and Bone Marrow Tumor Purging Cancer Res., November 1, 2001; 61(21): 7882 - 7888. [Abstract] [Full Text] [PDF]

				E. Casado, J. Gomez-Navarro, M. Yamamoto, Y. Adachi, C. J. Coolidge, W. O. Arafat, S. D. Barker, M. H. Wang, P. J. Mahasreshti, A. Hemminki, et al. Strategies to Accomplish Targeted Expression of Transgenes in Ovarian Cancer for Molecular Therapeutic Applications Clin. Cancer Res., August 1, 2001; 7(8): 2496 - 2504. [Abstract] [Full Text] [PDF]

				R. V. Iyengar, C. A. Pawlik, E. J. Krull, D. A. Phelps, R. A. Burger, L. C. Harris, P. M. Potter, and M. K. Danks Use of a Modified Ornithine Decarboxylase Promoter to Achieve Efficient c-MYC- or N-MYC-regulated Protein Expression Cancer Res., April 1, 2001; 61(7): 3045 - 3052. [Abstract] [Full Text]